Clinical Trial Update: Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for convalescent plasma and human intravenous immunoglobulin in hospitalized COVID-19 patients, covering Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Convalescent Plasma (PC) (convalescent plasma)
• Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) (intravenous immunoglobulin)

Snippet

Sponsor: Lifefactors Zona Franca, SAS | Conditions: Coronavirus Disease 2019 (COVID-19) | Phase 2, Phase 3 | Status: UNKNOWN